@article{3341006,
    title = "Surgical oncology during the post-COVID-19 era: What is next?",
    author = "Lianos, G.D. and Frountzas, M. and Schizas, D. and Baltagiannis, E.G. and Alexiou, G.A. and Bali, C. and Glantzounis, G.K. and Mitsis, M. and Vlachos, K.",
    journal = "International Journal of Surgical Oncology",
    year = "2023",
    volume = "127",
    number = "1",
    pages = "7-10",
    publisher = "John Wiley and Sons Inc",
    issn = "2090-1402, 2090-1410",
    doi = "10.1002/jso.27104",
    keywords = "cancer patient;  cancer recurrence;  cancer surgery;  cancer survival;  complication;  coronavirus disease 2019;  disease severity;  human;  pandemic;  recurrence risk;  Review;  surgical oncology;  tumor growth;  epidemiology;  neoplasm, COVID-19;  Humans;  Neoplasms;  Pandemics;  SARS-CoV-2;  Surgical Oncology",
    abstract = "During first outburst of COVID-19, several strategies had been applied for surgical oncology patients to minimize COVID-19 transmission. COVID-19 infection seemed to compromise survival and major complication rates of surgical oncology patients. However, survival, tumor progression and recurrence rates of surgical oncology patients were associated to the consequences of COVID-19 pandemic on their management. In addition, the severity of COVID-19 infections has been downgraded. Therefore, management of surgical oncology patients should be reconsidered. © 2022 Wiley Periodicals LLC."
}